CoChat

The use of SSRIs in children and adolescents

Hetrick, Sarah E, McKenzie, Joanne E, Merry, Sally N · 2010 · Current Opinion in Psychiatry
Cited by 36

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Introduction Depressive disorders are prevalent among young people [1,2] and are frequently untreated or inadequately treated [3]. The use of antidepressants in the management of depression in children and adolescents is contentious. Selective serotonin reuptake inhibitors (SSRIs) had been widely used in paediatric depression until warnings about their use were issued following concerns that children and adolescents who had participated in trials evaluating the effectiveness of SSRIs were at an increased risk of self-harm. This resulted in comprehensive reviews of the trials by government regulatory agencies which all concluded that only fluoxetine should be recommended for use in children and adolescents with depressive disorders [4–7]. Claims and counter claims about the effectiveness of SSRIs and risk related to their use have followed [8–13]. Concerns have been raised that if antidepressant use is limited young people could be deprived of effective treatments for a condition that carries with it considerable morbidity and mortality [8,9,14]. Recent research has suggested that pessimism about effective treatments has resulted in reluctance on the part of patients to seek help [15]. Further, lower rates of depressive disorder diagnoses [15] may indicate that clinicians are reluctant to make this diagnosis, perhaps due to uncertainty about effective treatments. The two key questions when considering the use of SSRIs in the treatment of children and adolescents with depressive disorder are, do they work and are they well tolerated? Answering these questions requires consideration of the evidence. Do selective serotonin reuptake inhibitors work? We undertook a Cochrane systematic review to evaluate the evidence about the effectiveness and risk of this class of medication for children and adolescents [16]. Twelve trials met the inclusion criteria for our review. The outcome ‘response’ was reported in all trials. This was a binary outcome created from a cut-point on a continuous depression scale. Both the scale and cut-point varied between trials. The pooled treatment effect of all SSRI compounds on the outcome ‘response’ demonstrated that a greater percentage of participants receiving SSRIs responded compared with those receiving placebo [relative risk (RR) 1.28; 95% confidence interval (CI) 1.17, 1.41] (Fig. 1).Figure 1: Relative risk of response to selective serotonin reuptake inhibitors compared with placeboThere was evidence that effectiveness of SSRIs on ‘response’ varied by compound (with 81.3% of the variation across SSRI compound effect estimates due to heterogeneity rather than chance; P = 0.001). There was a statistically significant difference in the percentage of children and adolescents who ‘responded’ when receiving fluoxetine compared with placebo (RR 1.86; 95% CI 1.49, 2.32). The percentage of those ‘responding’ while on fluoxetine ranged between 41 and 61% compared with a range of 20–35% in those on placebo. Depressive symptom scores [Children's Depression Rating Scale-Revised scale (CDRS-R); range 17–113] were also statistically significantly lower for those receiving fluoxetine compared with placebo at the end of treatment [ranging between 8 and 12 weeks of treatment; treatment effect 5.63 (95% CI −7.38, −3.88)]. For paroxetine, there was no statistically significant difference in the percentage of children and adolescents who ‘responded’ to paroxetine compared with those who ‘responded’ to placebo (RR 1.09; 95% CI 0.95, 1.26). There was a lack of consistency for both sertraline and citalopram. There was no statistically significant difference in ‘response’ rate between the sertraline and control groups (RR 1.17; 95% CI 1.00, 1.36). However, depressive symptom scores were significantly lower in the sertraline group (treatment effect CDRS-R 3.56; 95% CI −6.69, −0.42). There was a statistically significant difference in the percentage of children and adolescents who ‘responded’ when receiving citalopram/escitalopram (RR 1.30; 95% CI 1.02, 1.67), compared with placebo but no significant difference in depressive symptom score (CDRS-R). Functioning is perhaps the most relevant outcome for young people as it measures their ability to sustain school/work, interpersonal relations, and social functioning on a day-to-day basis [17]. There was no evidence that SSRIs were effective in improving functioning. What are the strengths and weaknesses of the evidence base? It is important to be cautious when interpreting the results of our review. The interpretation of the outcome ‘response’, the selection of patient outcomes, the clinical significance of treatment effects, and other issues of internal and external validity all need consideration. Outcome measurement In the search for effective treatments, the ideal goal is a resolution of symptoms (i.e., remission) and a return to normal function. In the trials in our review, remission or functioning were inconsistently reported, not reported, or not collect

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/yco.0b013e328334bc92

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 36

Metadata

Authors
Hetrick, S. E., McKenzie, J. E., & Merry, S. N.
Venue
Current Opinion in Psychiatry
Published
2010-01
Volume
23
Issue
1
Pages
53-57
ISSN
0951-7367 (ISSN-L)
OpenAlex
W2049618851
Cited by
36
References
11
FWCI
2.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.